abstract |
A33 related antigens PRO301, PRO362 and PRO245, are new. Independent claims are also included for the following: (1) a nucleic acid comprising DNA having at least 95% sequence identity to: (a) a DNA molecule encoding PRO301 comprising amino acids 28-235 of a 299 amino acid sequence (given in the specification); (b) a DNA molecule encoding the same mature polypeptide encoded by cDNA in ATCC 209432 (designated DNA40628-1216); or (c) the complement of DNA in (a); (2) a nucleic acid comprising DNA having at least 80% sequence identity to: (a) a DNA molecule encoding PRO362 comprising amino acids 1-321 or 1-X (X = any of residues 271-280) of a 321 amino acid sequence (given in the specification); (b) a DNA molecule encoding the same mature polypeptide encoded by cDNA in ATCC 209620 (designated DNA45416-1251); or (c) the complement of DNA in (a); (3) production of PRO301, PRO362 or PRO245; isolated PRO301 comprising residues 28-235 of the 299 residue sequence; (4) isolated PRO362 comprising residues 1-229 or 1-X (X = 271-280) of the 321 residue sequence; (5) an isolated antibody which binds PRO301 or PRO362; (6) treating an inflammatory disease by administering a therapeutically effective amount of a PRO301, PRO362 or PRO245 antagonist or fragment; determining the presence of PRO301, PRO362 or PRO245; and (7) diagnosis of an inflammatory disease or tumor, by detecting the level of PRO301, PRO362 or PRO245 gene expression. ACTIVITY : Cytostatic; Anti-inflammatory. MECHANISM OF ACTION : Antagonist. |